Related Experiment Video
Updated: May 22, 2026

Generating a Reproducible Model of Mid-Gestational Maternal Immune Activation using Poly(I:C) to Study Susceptibility and Resilience in Offspring
Published on: August 17, 2022
Pregnancy outcome after paternal exposure to azathioprine/6-mercaptopurine
Maria Hoeltzenbein1, Corinna Weber-Schoendorfer, Cornelia Borisch
1Pharmakovigilanzzentrum Embryonaltoxikologie, Charité Universitätsmedizin Berlin, Germany. Maria.Hoeltzenbein@charite.de
Abstract:
There are only few studies with conflicting results on pregnancy outcome after paternal exposure to azathioprine or 6-mercaptopurine. In our study, pregnancy outcome of 115 prospectively followed pregnancies after paternal exposure to azathioprine or 6-mercaptopurine is compared to a control group of 341 pregnancies. The rate of major malformations was not increased (3.0% in exposed versus 2.2% in the control group). There was no specific pattern of birth defects and no indication for chromosomal aberrations in the exposed group. We observed a higher rate of elective terminations of pregnancy in the exposed group and a non-significant increase of spontaneous abortions (cumulative incidence 19% versus 13%, respectively). Further prospective studies are required to address the question of a possibly increased risk for spontaneous abortion.
Related Concept Videos
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Teratogenicity
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Spermatogenesis
